Jounce Therapeutics, Inc. (JNCE) is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/.
The Head of Pharmacovigilance will oversee all global pharmacovigilance activities for all Jounce clinical programs, including activities performed at Clinical Research Organizations and in collaboration with partners on Jounce clinical trials to ensure compliance with regulatory requirements, internal procedures and policies, GCP, and to ensure readiness for regulatory inspections and audits.